|
Collados-Ros A, Muro M, Legaz I. Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms-A Systematic Review. Biomedicines. 2024 Jan 17;12(1):208. doi: 10.3390/biomedicines12010208. PubMed PMID: 38255313; PubMed Central PMCID: PMC10813452.
AÑO: 2024; IF: 3.9
|
38255313
|
Legaz I, Navarro-Noguera E, Collados-Ros A, Bolarin JM, Muro M. Biomarkers of Innate Immunity and Immunological Susceptibility to Viral Infection in Patients with Alcoholic Cirrhosis. Biomedicines. 2024 Feb 1;12(2):336. doi: 10.3390/biomedicines12020336. PubMed PMID: 38397937; PubMed Central PMCID: PMC10887413.
AÑO: 2024; IF: 3.9
|
|
Botella C, Galian JA, Jimenez-Coll V, Fernandez-Gonzalez M, Morales F, Martinez-Gomez G, Gonzalez-Lopez R, Alegria MJ, Moya MR, Martinez-Banaclocha H, Minguela A, Legaz I, Llorente S, Muro M. Early Monitoring of Donor-Derived Cell-Free DNA in Kidney Allograft Recipients Followed-Up for Two Years: Experience of One Center. Life (Basel). 2024 Nov 16;14(11):1491. doi: 10.3390/life14111491. PubMed PMID: 39598289; PubMed Central PMCID: PMC11595986.
AÑO: 2024; IF: 3.4
|
|
Morales R, Bolarin JM, Muro M, Legaz I. Presence of KIR2DL2/S2, KIR2DL5, and KIR3DL1 Molecules in Liver Transplant Recipients with Alcoholic Cirrhosis Could Be Implicated in Death by Graft Failure. Diagnostics (Basel). 2023 Mar 23;13(7):1217. doi: 10.3390/diagnostics13071217. PubMed PMID: 37046435; PubMed Central PMCID: PMC10093628.
AÑO: 2023; IF: 3.0
|
|
Legaz I, Muro M. Natural Killer Cells and Their Implications in Immune Response Diversification in Clinical Pathology and Neoplastic Processes. Int J Mol Sci. 2023 Apr 24;24(9):7743. doi: 10.3390/ijms24097743. PubMed PMID: 37175450; PubMed Central PMCID: PMC10178591.
AÑO: 2023; IF: 4.9
|